Asset
BEMPEGALDESLEUKIN
NEKTAR THERAPEUTICS COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04955262 | phase1 | withdrawn | 2019-08-01 | 2021-06-01 | Nektar Therapeutics | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab |
| NCT02869295 | phase1_2 | completed | 2015-12-01 | 2018-10-31 | Nektar Therapeutics | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
| NCT04646044 | phase1 | completed | 2020-11-13 | 2021-05-11 | Nektar Therapeutics | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 |
| NCT03785925 | phase2 | completed | 2019-04-29 | 2022-02-09 | Nektar Therapeutics | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer |
| NCT03729245 | phase3 | terminated | 2018-12-18 | 2022-01-07 | Nektar Therapeutics | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) |
FDA applications (0)
This company has no applications containing this asset.